Compare Illumina, Inc. (ILMN) vs Lithium Americas Corp (LAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Lithium Americas Corp — how do they compare? Illumina, Inc. trades at $278 (market cap $39.95B), while Lithium Americas Corp trades at $2.36 (market cap $850.38M). The key difference: Illumina, Inc. is far larger — about 47× Lithium Americas Corp's market cap, and Illumina, Inc. is trading nearer its 52-week high, Lithium Americas Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Lithium Americas Corp for 27 Days on average.
| ILMN | LAC | |
|---|---|---|
Market Cap | $39.95B | $850.38M |
Volume | 3,169,503 | 8,804,637 |
Sector | Health | Basic Materials |
52-Week High | $293.69 | $10.05 |
52-Week Low | $91.00 | $2.36 |
Typical Hold Time | 83 Days | 27 Days |
Enterprise Value | $41.31B | $1.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $271.02, up 1.22% and near its 52-week high, reflecting strong momentum. The stock exhibits a bullish technical trend with recent earnings beats and a positive analyst consensus. Revenue for 2025 was $4.34B with net income of $850M, marking a significant profit margin recovery. Cash flow from operations remains robust at $1.08B, supporting financial stability. Inclusion in the S&P 500 and focus on AI-driven genomics growth are key catalysts.
Outlook is positive given earnings momentum and strategic initiatives, but risks include valuation premiums and competitive pressures. The stock offers growth exposure to genomic innovation, though investors should monitor execution on AI integration and margin sustainability. Analyst price targets suggest moderate upside from current levels, with consensus at $241.00.
Lithium Americas (LAC) trades at $2.36, down 2.28% with bearish technical signals but positive analyst sentiment. The company shows negative profitability metrics with ROE at -9.56% and net income of -$122.09M for 2025, though it has beaten EPS estimates in recent quarters. Strong financing activity ($1.14B in 2025) supports Thacker Pass development, a key growth catalyst.
Investment outlook balances development potential against current losses. The consensus price target of $4.00 suggests 70% upside, but execution risks and lithium price volatility remain concerns. Construction progress at Thacker Pass could drive rerating, though the stock faces near-term pressure from negative cash flow and market skepticism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Lithium Americas Corp
Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →
